SciClone Pharmaceuticals, seems to be undervalued based on Macroaxis valuation methodology. This module measures value of SciClone Pharmaceuticals, from inspecting the company fundamentals such as Operating Margin of
25.82%, Return On Equity of 19.56% and Shares Outstanding of 52.19M as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other.
Valuation Drivers Correlation
|Click cells to compare fundamentals||View All Correlations|
|Horizon||30 Days Login to change|
SciClone Pharmaceuticals, In is currently regarded as top stock in price to earning category among related companies. It is rated below average in price to book category among related companies fabricating about 0.17 of Price to Book per Price to Earning. The ratio of Price to Earning to Price to Book for SciClone Pharmaceuticals, In is roughly 5.90
|Price to Earning ( times )|
|Price to Book ( times )|